Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLI1 | P08151 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CYP46A1 | Q9Y6A2 | 4/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9128397 | 1.00 | GLI1 (0.36) | GLI1EPHX2CYP2D6BCHEDPP4 | |
| SCHEMBL24511671 | 1.00 | GLI1 (0.36) | GLI1EPHX2CYP2D6BCHEDPP4 | |
| SCHEMBL197080 | 0.89 | — | — | |
| SCHEMBL21545609 | 0.89 | GLI1 (0.41) | GLI1CYP2D6BCHEDPP4MME | |
| SCHEMBL2950685 | 0.80 | LMNA (0.43) | GLI1BCHEDPP4MMEHTT | |
| SCHEMBL2950683 | 0.80 | LMNA (0.43) | GLI1BCHEDPP4MMEHTT | |
| SCHEMBL8181948 | 0.80 | GLI1 (0.36) | GLI1CYP2D6BCHEDPP4MME | |
| SCHEMBL13783333 | 0.80 | GLI1 (0.36) | GLI1CYP2D6BCHEDPP4MME | |
| SCHEMBL12437074 | 0.80 | GLI1 (0.36) | GLI1CYP2D6BCHEDPP4MME | |
| SCHEMBL14492218 | 0.80 | GLI1 (0.36) | GLI1CYP2D6BCHEDPP4MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023205701-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-4259632-A1 | N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE AND N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE DERIVATIVES AS IRAK4 INHIBITORS FOR THE TREATMENT OF ASTHMA | Astrazeneca AB (SE) | 2023-10-18 | — | — | EP | disclosed |
| CN-116583285-A | N- (imidazo [1,2-b ] pyridazin-3-yl) -1-cyclohexyl-2H-indazole-5-carboxamide and N- (pyrazolo [1,5-a ] pyrimidin-3-yl) -1-cyclohexyl-2H-indazole-5-carboxamide derivatives as IRAK4 inhibitors for the treatment of asthma | 阿斯利康(瑞典)有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20230219951-A1 | PYRIDINE-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| WO-2022122876-A1 | N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE AND N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE DERIVATIVES AS IRAK4 INHIBITORS FOR THE TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122876-A1 | N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE AND N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE DERIVATIVES AS IRAK4 INHIBITORS FOR THE TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | WO | disclosed |
| EP-2980067-B1 | PROCESSES FOR PREPARING OPTICALLY ACTIVE DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2017-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | GLI1 89/4885EPHX2 3297/4885CYP2D6 4603/4885 |
| US-20230219951-A1 | PYRIDINE-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | WEE1, SOS1, HINT1 | GLI1 2637/4885EPHX2 2254/4885CYP2D6 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.